January 5, 2018
USADA announced today that James Vennera, of Rutherfordton, N.C., an athlete in the sport of archery, has accepted a public warning for his rule violation. USADA found that the violation was unintentional and resulted from his use of metoprolol, a prescription medication used under the care of a physician. Vennera, 68, had forthrightly declared use of his medication on his doping control form at the time of sample collection and subsequently obtained a Therapeutic Use Exemption (TUE) authorizing future use of this medication in sport.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at email@example.com, by phone at 1-877-Play Clean (1-877-752-9253) or by mail at the address below.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.